As for anti-IL6 strategies, their efficacy in improving the principal outcomes of COVID-19 continues to be controversial according to an updated Cochrane systematic review [19], in spite of the amount of available data, while the use of other immunosuppressants cannot be recommended at this time [20,21,22]. This evidence concerns the gene IL6 and COVID-19.